NasdaqCM - Delayed Quote USD

Abeona Therapeutics Inc. (ABEO)

Compare
6.02 +0.22 (+3.79%)
At close: September 20 at 4:00 PM EDT
6.05 +0.03 (+0.50%)
After hours: September 20 at 5:37 PM EDT
Advanced Chart
Loading Chart for ABEO
DELL
  • Previous Close 5.80
  • Open 5.81
  • Bid 5.94 x 100
  • Ask 6.01 x 100
  • Day's Range 5.72 - 6.02
  • 52 Week Range 3.05 - 9.01
  • Volume 416,973
  • Avg. Volume 303,057
  • Market Cap (intraday) 260.753M
  • Beta (5Y Monthly) 1.51
  • PE Ratio (TTM) --
  • EPS (TTM) -1.77
  • Earnings Date Nov 11, 2024 - Nov 15, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 15.92

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

www.abeonatherapeutics.com

84

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Abeona Therapeutics Inc.

Recent News: ABEO

View More
View More

Performance Overview: ABEO

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ABEO
20.16%
S&P 500
19.55%

1-Year Return

ABEO
58.84%
S&P 500
28.32%

3-Year Return

ABEO
79.93%
S&P 500
28.64%

5-Year Return

ABEO
92.57%
S&P 500
89.66%

Compare To: ABEO

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

ABEO
Abeona Therapeutics Inc.
6.02
+3.79%
Mkt Cap 260.753M
Industry Biotechnology
SNDX
Syndax Pharmaceuticals, Inc.
18.27
-1.93%
Mkt Cap 1.555B
Industry Biotechnology
KRYS
Krystal Biotech, Inc.
184.17
-0.17%
Mkt Cap 5.291B
Industry Biotechnology
ADAP
Adaptimmune Therapeutics plc
0.9961
-1.38%
Mkt Cap 254.748M
Industry Biotechnology
HRTX
Heron Therapeutics, Inc.
2.0600
+1.98%
Mkt Cap 312.436M
Industry Biotechnology
URGN
UroGen Pharma Ltd.
13.54
-2.24%
Mkt Cap 570.225M
Industry Biotechnology
CKPT
Checkpoint Therapeutics, Inc.
2.4100
-0.82%
Mkt Cap 108.493M
Industry Biotechnology
XFOR
X4 Pharmaceuticals, Inc.
0.7070
-0.08%
Mkt Cap 119.13M
Industry Biotechnology
ACRV
Acrivon Therapeutics, Inc.
7.47
-1.58%
Mkt Cap 231.362M
Industry Biotechnology
ATNM
Actinium Pharmaceuticals, Inc.
1.8000
-4.26%
Mkt Cap 56.078M
Industry Biotechnology
MREO
Mereo BioPharma Group plc
4.2500
-0.70%
Mkt Cap 653.875M
Industry Biotechnology

Statistics: ABEO

View More

Valuation Measures

Annual
As of 7/12/2024

  • Market Cap

    260.75M

  • Enterprise Value

    161.21M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    37.76

  • Price/Book (mrq)

    3.56

  • Enterprise Value/Revenue

    53.29

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -37.81%

  • Return on Equity (ttm)

    -127.38%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -52.6M

  • Diluted EPS (ttm)

    -1.77

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    122.71M

  • Total Debt/Equity (mrq)

    31.63%

  • Levered Free Cash Flow (ttm)

    -20.5M

View More

Research Analysis: ABEO

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

7.50
15.92 Average
6.02 Current
21.00 High
 
View More

Company Insights: ABEO

People Also Watch

MREO Mereo BioPharma Group plc
4.2500
-0.70%
 
ADVM Adverum Biotechnologies, Inc.
7.49
-0.13%
 
AKBA Akebia Therapeutics, Inc.
1.3700
0.00%
 
ALDX Aldeyra Therapeutics, Inc.
5.89
-2.48%
 
AFMD Affimed N.V.
3.6900
-6.82%
 
VYGR Voyager Therapeutics, Inc.
6.25
-1.11%
 
CLSD Clearside Biomedical, Inc.
1.3100
+2.34%
 
PIRS Pieris Pharmaceuticals, Inc.
17.24
+0.70%
 
VSTM Verastem, Inc.
2.8800
+1.77%
 
ALRN Aileron Therapeutics, Inc.
3.7300
+28.18%
 
ABUS Arbutus Biopharma Corporation
4.0200
-2.90%
 
GLYC GlycoMimetics, Inc.
0.1648
-3.06%
 
FBIO Fortress Biotech, Inc.
1.4950
-18.75%
 
ADMA ADMA Biologics, Inc.
19.98
+1.22%
 
SLDB Solid Biosciences Inc.
7.86
-1.75%
 
CDTX Cidara Therapeutics, Inc.
11.27
-3.84%